ELUCIDATE Study Demonstrates 93 Percent Accuracy with Strong Performance in the “Gray Zone” for Elucid’s FDA-cleared FFR-IQ™
Data presented at TCT 2026 demonstrate highest sensitivity and specificity of any FFR-CT validation study BOSTON and TCT 2026, SAN DIEGO – Nov. 3, 2026 – Elucid, an innovator of AI-powered cardiovascular imaging software, today announced results from ELUCIDATE, presented at the annual Transcatheter Cardiovascular Therapeutics Conference (TCT 2026). The ELUCIDATE study, which supported Elucid’s […]
Elucid Statement on Heartflow Lawsuit: Reaffirms Mission, Confidence in Its Technology, and Commitment to Patients and Physicians
Boston – October 23, 2026 – Elucid Bioimaging Inc. (“Elucid”) today reaffirmed its commitment to advancing its mission – the prediction and personalization of the prevention of heart attack and stroke – and its confidence in the technology and intellectual property behind its products. Elucid is aware of a lawsuit filed by Heartflow, Inc., on […]
Elucid Announces FDA Clearance of FFR-IQ™ and Commercial Availability of the Most Accurate¹ FFR-CT Software
Company’s BioIntegrated FFR-CT combines anatomy and biology to noninvasively estimate Fractional Flow Reserve and enable precise treatment of cardiovascular disease BOSTON, Oct. 21, 2026 – Elucid, an innovator of AI-powered cardiovascular imaging software, today announced U.S. Food and Drug Administration (FDA) 510(k) clearance of FFR-IQ™, its software for noninvasive estimation of fractional flow reserve from […]
Elucid Appoints Mark Miller as Chief Revenue Officer to Lead Commercial Expansion Ahead of BioIntegrated FFR-CT Launch
Veteran cardiovascular imaging and diagnostics sales leader to drive go-to-market strategy as Elucid prepares for FDA clearance of FFR-CT BOSTON— Sept. 29, 2026 — Elucid, a medical technology company using AI-powered, clinically validated software to advance precision diagnosis of cardiovascular disease, today announced that Mark Miller has joined the company as chief revenue officer (CRO). […]
Elucid Raises $55 Million in Oversubscribed Series D Financing
Funding will accelerate commercialization of Elucid’s AI-powered cardiovascular imaging platform and expand strategic partnerships with leading medical technology companies BOSTON — Sept. 2, 2026 — Elucid, a medical technology company using AI-powered, clinically validated software to advance precision diagnosis and treatment of cardiovascular disease, today announced the raise of $55 million in an oversubscribed Series […]
Elucid Announces First Patient Enrollment in AI-PREDICT, a Landmark International Study to Define Lesion-Level Cardiovascular Risk
Elucid, an innovator in AI-powered coronary CT angiography (CCTA) analysis, today announced first patient enrollment in AI-PREDICT, a retrospective, international, multicenter study designed to establish a new lesion-centric paradigm for cardiovascular risk stratification.
Elucid to Showcase CCTA Vision at SCCT 2026, Defining the Future of Personalized Cardiovascular Care
Elucid, an innovator in AI-powered coronary CT angiography (CCTA) analysis, today announced its largest and most comprehensive presence to date at the Society of Cardiovascular Computed Tomography Annual Scientific Meeting (SCCT 2026), taking place July 9 – 12, 2026, at the Gaylord Pacific Resort & Convention Center in Chula Vista, Calif.
Elucid’s Plaque-IQ™ Named “Best New Cardiology Technology Solution” in 2026 MedTech Breakthrough Awards Program
Elucid today announced that its Plaque-IQ arterial plaque analysis software has been selected as winner of the “Best New Cardiology Technology Solution” award in the 10th annual MedTech Breakthrough Awards.
Elucid’s PlaqueIQ Image Analysis Software Included in EviCore Coverage Guidelines
Elucid, an AI medical technology company focused on providing physicians with a more precise view of atherosclerosis to drive patient-specific therapeutic decisions, today announced that EviCore, a radiology benefit manager, has updated its cardiac imaging guidelines to include coverage of coronary computed tomography angiography (CTA) plaque quantification (see pages 82-84), effective October 1, 2025.
Elucid Announces CCTA Reimbursement to be Doubled with CMS Rule
Elucid has announced a final rule from US Centers for Medicare & Medicaid Services (CMS) that will significantly increase the reimbursement for cardiac computed tomography angiography (CCTA).
